Results 61 to 70 of about 16,645 (269)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. [PDF]

, 2019
AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational,
Abozguia, K, Camm, J, Cappato, R, Diener, H-C, Grimaldi, M, Heidbüchel, H, Hohnloser, SH, Kautzner, J, Mont, L, Morillo, CA, Mönninghoff, C, Rauer, H, Reimitz, P-E, Smolnik, R   +13 more
core   +2 more sources

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study

Thrombosis Journal, 2022
Background Appropriate and timely anticoagulant therapy with vitamin K antagonists (VKAs) or non-vitamin K oral antagonists (NOACs) is essential for stroke prevention in non-valvular atrial fibrillation (NVAF).
Christopher Hohmann, Magnus Lutz, Sheila Vignali, Kathrin Borchert, Karolin Seidel, Sebastian Braun, Stephan Baldus, Michael Näbauer   +7 more
doaj   +1 more source

A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol. [PDF]

, 2019
BACKGROUND: Treatment with anticoagulants, including direct oral anticoagulants (DOACs), should be considered for patients diagnosed with atrial fibrillation (AF) deemed at risk of ischaemic stroke.
Bhat, Y, Dixit, A, Mistri, A, Patel, B, Quoraishi, SH, Uprichard, J   +5 more
core   +1 more source

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik, Ainhoa Gomez‐Lumbreras, Guilherme Del Fiol, Kensaku Kawamoto, Katy E. Trinkley, Thomas Reese, Aubrey Jones, Daniel C. Malone   +7 more
wiley   +1 more source

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE

Clinical and Applied Thrombosis/Hemostasis, 2023
Patients treated with edoxaban may require diagnostic and therapeutic procedures that involve edoxaban interruption. Although heparin bridging strategies are not recommended, heparin is frequently used in clinical practice.
Amparo Santamaria MD, PhD, Cathy Chen MD, Paolo Colonna MD, FESC, Christian von Heymann MD, PhD, Manish Saxena MBBS, MSc, FBHS, Thomas Vanassche MD, PhD, James Jin PhD, Martin Unverdorben MD, PhD   +7 more
doaj   +1 more source

Rapid Assay for the Therapeutic Drug Monitoring of Edoxaban

Biomolecules, 2022
Edoxaban is a direct oral anticoagulant (DOAC) that has been recently indicated for the treatment of pulmonary embolism (PE) in SARS-CoV-2 infections. Due to its pharmacokinetic variability and a narrow therapeutic index, the safe administration of the drug requires its therapeutic drug monitoring (TDM) in patients receiving the treatment. In this work,
Md Abdur Rashid, Saiqa Muneer, Yahya Alhamhoom, Nazrul Islam   +3 more
openaire   +4 more sources

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia [PDF]

Case Reports in Vascular Medicine, 2020
Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse drug reaction of heparin therapy, which increases a patient’s risk of developing venous and/or arterial thromboembolism. HIT should be treated through discontinuation of heparin and administration of nonheparin anticoagulants such as argatroban.
Ryo Kanamoto, Shinichi Hiromatsu, Tomoyuki Anegawa, Kanako Sakurai, Shohei Yoshida, Yusuke Shintani, Hiroyuki Otsuka, Satoru Tobinaga, Hiroyuki Tanaka   +8 more
openaire   +4 more sources

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen, Xiaofeng Wu, Jian Lin, Narayan Cheruvu, Susan R. Raber, Maria Lavinea Novis de Figueiredo, Manthena V. S. Varma   +6 more
wiley   +1 more source

Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis

Scientific Reports
Portal vein thrombosis (PVT) worsens the long-term prognosis of patients with cirrhosis; however, the optimal treatment remains to be determined. Reports on the efficacy of direct oral anticoagulants are increasing, and further evidence is needed ...
Tomoko Tadokoro, Joji Tani, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Koji Fujita, Takako Nomura, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Masafumi Ono, Tsutomu Masaki   +13 more
doaj   +1 more source